Chia Tai Tianqing starts QT safety study for myelofibrosis drug TQ05105
The Phase 1 cardiac-safety trial in healthy volunteers backs a pipeline that already spans two myelofibrosis studies and a chronic GVHD program for the same molecule.
Executive Summary
- Chia Tai Tianqing Pharmaceutical Group has registered a Phase 1 study to characterize the cardiac-safety profile of its investigational drug TQ05105 in healthy volunteers, using a design built to detect QT-interval prolongation, a marker of arrhythmia risk.
- TQ05105 is already being tested in multiple ongoing myelofibrosis trials and a chronic graft-versus-host disease trial, so this safety study functions as supporting evidence for a broader clinical program rather than a standalone catalyst.
- The trial uses an active comparator and a placebo arm in the same healthy-volunteer population, the standard structure regulators expect before a drug advances further in cardiac-sensitive settings.
- The sponsor's broader TQ05105 program includes two prior myelofibrosis trials that were terminated, alongside multiple trials still recruiting, a mixed record that this safety study does not resolve but that frames how much is riding on the molecule's continued development.
The new trial
The study, filed under NCT07708272, will enroll 60 healthy adults aged 18 to 45 in China to measure the placebo-corrected change from baseline in the QT interval corrected by Fridericia's method (ΔΔQTcF), the trial's registered primary endpoint. The design uses a triple-masked, four-arm crossover structure with moxifloxacin hydrochloride as an active positive control and placebo as the negative control, a standard approach for characterizing a drug's effect on cardiac repolarization before broader clinical use. Secondary endpoints track adverse events, pharmacokinetic measures including peak concentration and half-life, and Holter-derived heart rate, PR interval, and RR interval over 26 days after the first dose. NCT07708272QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy ParticipantsNCT07708272
Timing and status
The trial has not yet begun recruiting, with a start date of July 1, 2026, and a registered primary completion date of December 1, 2026, and full completion targeted for February 1, 2027. The registry listing was added on July 16, 2026, and no protocol amendments have followed yet, which is expected for a trial at this stage. NCT07708272+1QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy ParticipantsNCT07708272QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy ParticipantsJul 16, 2026
Where TQ05105 stands
TQ05105 is not a standalone asset. Chia Tai Tianqing is running the drug across at least 17 registered trials, including a Phase 2 study in intermediate/high-risk myelofibrosis (NCT07551427), a combination Phase 1/2 myelofibrosis trial pairing TQ05105 with TQB3617 (NCT06122831), and a Phase 2 trial in chronic graft-versus-host disease (NCT06300320), all currently recruiting. Two earlier trials in the same molecule, a Phase 1/2 myelofibrosis combination study with TQB3909 (NCT06245941) and a Phase 1 study in ruxolitinib-resistant or intolerant myelofibrosis patients (NCT06388759), were terminated. The QT study now sits alongside a pharmacokinetics trial in hepatic-impairment subjects and a drug-interaction study with rabeprazole, both also in early-stage recruitment status, rounding out the supporting safety and PK work behind the myelofibrosis and GVHD programs.
Sponsor track record
Chia Tai Tianqing has completed 75 of 105 trials with a recorded outcome and terminated 30, a 71% completion rate across its broader portfolio, and the company runs 383 trials in total across all statuses. That scale positions TQ05105 as one program within a large industrial pipeline rather than a bet-the-company asset, and the cardiac-safety study reads as routine due diligence supporting an already-active clinical effort rather than a signal of new strategic direction.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.